类风湿关节炎患者COVID-19风险增加:一项基于一般人群的队列研究
基于健康改善网络(Health Improvement Network)的队列研究显示,在17268例类风湿关节炎(RA)患者中观察到225例疑似和确诊COVID-19,一般人群1616600例中观察到14234例,调整后风险比(HRadj)为1.19(95%CI 1.04-1.36);确诊COVID-19在RA患者中为46例,一般人群中为2249例,HRadj为1.42(95%CI 1.01-1.95)。骨关节炎患者与一般人群之间无疑似和确诊或确诊COVID-19率的统计学显著差异。作者结论认为RA而非骨关节炎与COVID-19风险增加相关,并建议鼓励RA患者接种加强疫苗及优先获得抗SARS-CoV-2单克隆抗体治疗。
要点
- RA患者疑似和确诊COVID-19的调整后HR为1.19(95%CI 1.04-1.36),确诊COVID-19的调整后HR为1.42(95%CI 1.01-1.95)。
- 骨关节炎患者与一般人群之间无疑似和确诊(HR 1.00 [95%CI 0.93-1.07])或确诊(HR 1.08 [95%CI 0.92-1.27])COVID-19率的统计学显著差异。
- 作者结论认为RA而非骨关节炎与COVID-19风险增加相关,并建议鼓励RA患者接种加强疫苗及优先获得抗SARS-CoV-2单克隆抗体治疗。
核心结论
- RA而非骨关节炎与COVID-19风险增加相关。
- 作者认为研究结果提供了及时证据,支持鼓励RA患者接种加强疫苗及优先获得抗SARS-CoV-2单克隆抗体治疗的建议。
研究设计与样本
- 使用健康改善网络(Health Improvement Network)识别2020年2月前的RA患者并随访至2020年9月,计算RA参与者COVID-19发生率并与一般人群比较。
- 采用Cox比例风险模型,通过暴露评分重叠加权调整潜在混杂因素。
- 在骨关节炎(非自身免疫性风湿病)参与者中重复相同分析作为阴性对照暴露。
主要发现
- 在17268例RA患者中识别出225例疑似和确诊COVID-19,一般人群1616600例中识别出14234例(1.4 vs 0.9/1000人月),调整后HR为1.19(95%CI 1.04-1.36)。
- 确诊COVID-19在RA患者中为46例,一般人群中为2249例(0.3 vs 0.1/1000人月),调整后HR为1.42(95%CI 1.01-1.95)。
- 骨关节炎参与者与一般人群之间疑似和确诊COVID-19率(HR 1.00 [95%CI 0.93-1.07])或确诊COVID-19率(HR 1.08 [95%CI 0.92-1.27])无统计学显著差异。
关键数值与推荐
- RA患者疑似和确诊COVID-19:225/17268例,发生率1.4/1000人月,调整后HR 1.19(95%CI 1.04-1.36)。
- RA患者确诊COVID-19:46/17268例,发生率0.3/1000人月,调整后HR 1.42(95%CI 1.01-1.95)。
- 一般人群疑似和确诊COVID-19:14234/1616600例,发生率0.9/1000人月。
- 一般人群确诊COVID-19:2249/1616600例,发生率0.1/1000人月。
- 骨关节炎与一般人群比较:疑似和确诊COVID-19 HR 1.00(95%CI 0.93-1.07),确诊COVID-19 HR 1.08(95%CI 0.92-1.27)。
临床怎么用
- 作者认为研究结果提供及时证据,支持鼓励RA患者接种加强疫苗及优先获得抗SARS-CoV-2单克隆抗体治疗的建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with rheumatoid arthritis (RA) are at an increased risk of acquiring infections owing to immunologic dysfunction and use of potent immunomodulatory medications; however, few data are available on their risk of COVID-19. We estimated the rate of COVID-19 among RA participants and compared it with that of the general population. METHODS: Using the Health Improvement Network, we identified RA patients before February 2020 and followed them to September 2020. We calculated the rate of COVID-19 among participants with RA and compared it with that of the general population using a Cox proportional hazards model, adjusting for potential confounders using overlap weighting of exposure score. We repeated the same analysis among participants with osteoarthritis, a nonautoimmune rheumatic disease, as a negative control exposure. RESULTS: We identified 225 cases of suspected and confirmed COVID-19 among 17,268 RA patients, and 14,234 cases among 1,616,600 participants in the general population (1.4 versus 0.9/1,000 person-months), with the adjusted hazard ratio (HRadj ) being 1.19 (95% confidence interval [95% CI] 1.04-1.36). Confirmed COVID-19 cases developed in 46 RA participants and in 2,249 in the general population (0.3 versus 0.1/1,000 person-months), with the HRadj being 1.42 (95% CI 1.01-1.95). No statistically significant difference was observed for suspected and confirmed (HR 1.00 [95% CI 0.93-1.07]) or confirmed (HR 1.08 [95% CI 0.92-1.27]) COVID-19 rates between participants with osteoarthritis and the general population. CONCLUSION: RA, but not osteoarthritis, was associated with an increased risk of COVID-19. Our findings provide timely evidence to support recommendations that booster vaccines and priority access to anti-SARS-CoV-2 monoclonal antibody treatments should be encouraged for RA patients.
引用
- Wang Y, D'Silva KM, Jorge AM, et al. Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A General Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2022. PMID: 34874123. doi:10.1002/acr.24831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。